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Abstract
Estrogen receptor -positive (ER-positive) or ‘luminal’ breast cancers were notoriously difficult to establish as
patient-derived xenografts (PDXs). We and others recently demonstrated that the microenvironment is critical
for ER-positive tumor cells; when grafted as single cells into milk ducts of NOD Scid gamma females, >90%
of ER-positive tumors can be established as xenografts and recapitulate many features of the human disease
in vivo. This intraductal approach holds promise for personalized medicine, yet human and murine stroma are
organized differently and this and other species specificities may limit the value of this model. Here, we analyzed
21 ER-positive intraductal PDXs histopathologically. We found that intraductal PDXs vary in extent and define
four histopathological patterns: flat, lobular, in situ and invasive, which occur in pure and combined forms. The
intraductal PDXs replicate earlier stages of tumor development than their clinical counterparts. Micrometastases
are already detected when lesions appear in situ. Tumor extent, histopathological patterns and micrometastatic
load correlate with biological properties of their tumors of origin. Our findings add evidence to the validity of the
intraductal model for in vivo studies of ER-positive breast cancer and raise the intriguing possibility that tumor
cell dissemination may occur earlier than currently thought.
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Breast cancer (BC) is a frequent disease worldwide
[1]. Over 75% of BCs express estrogen receptor (ER)
in >1% of the tumor cells by immunohistochemistry
(IHC) [2] and overlap with luminal A and B subtypes
defined by global gene expression [3,4] exhibiting low
versus high proliferative indices and distant recurrence
rates [5]. Twenty percent of patients experience distant
recurrence and cancer-related death [6]. Overtreatment
of early disease and endocrine resistance are additional
problems concerning this subgroup [7]. A lack of pre-
clinical models hampered progress in understanding
the biology of luminal tumors and the development of
new therapies. Genetically engineered mouse models
mostly develop ER-negative tumors; few ER-positive
BC cell lines grow in vivo requiring non-physiological
estrogen supplements [8]. Patient-derived xenografts
(PDXs) are increasingly used but difficult to establish
from ER-positive tumors [8]. We and others showed
that the microenvironment is a major determinant of
luminal BC cells and that take rates increase dramat-
ically when luminal BC cells are grafted to mouse
milk ducts [9]. They grow without estrogen sup-
plementation, recapitulating many features of their
clinical counterpart [9,10]. Yet, mammary stroma and
endocrine milieu differ between women and mice. To
assess the impact of the mouse host on the biology of the
engrafted human cells, we analyzed 21 intraductal PDXs
histopathologically.
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any
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Materials and methods
The study was approved by the Commission cantonale
d’éthique de la recherche sur l’être humain (CER-VD
38/15); patients signed informed consent. Animal
experiments were performed in accordance with proto-
col 1861.3 approved by Service de la Consommation et
des Affaires Vétérinaires, Canton de Vaud, Switzerland.
After inking of margins and macroscopic assessment,
part of the tumor tissue was taken by the pathologist
(MF), transported to the laboratory in DMEM/F12,
mechanically and enzymatically dissociated to single
cells, lentivirally transduced with luciferase-Green
Fluorescent Protein (GFP) and injected into teats
of 10-week-old NOD Scid gamma females [9]. In
vivo growth was monitored biweekly by biolumi-
nescence. Engrafted glands were dissected, fixed in
buffered formalin for 2 h and paraffin embedded. Four
micrometer sections were cut and numbers 1, 7 and 15
stained with hemalun/eosin. Staining for Alu elements
unequivocally identified human cells when required.
IHC was performed on Discovery Ventana ULTRA [9].
Micrometastatic loadwas calculated as the percentage of
bioluminescence-positive organs of all organs collected.
Results
Tumor cells from 21 patients were intraductally grafted
to 88 mice in 220 glands after lentiviral transduction
with luciferase-GFP (Figure 1A,B, supplementary
material, Table S1). Mice were sacrificed when radi-
ance >10E8 so tumor cells are readily detectable.
Micrometastases, consisting of <30 cells (Figure 1C),
were detected in 90% of the 31 mice analyzed by
ex vivo radiance measurements on various organs,
revealing bones as the most frequent site of tumor
cell seeding, followed by brain, lungs and liver
(Figure 1D). Tumor extent assessed semiquantita-
tively on hemalun/eosin-stained sections varied, with
≥70% of ducts distended by human cells in six of 21
PDXs (see supplementary material, Figure S1A) and
tumor cell foci occupying 20–60% or<5% of the ductal
tree in 10 and 5 PDXs, respectively (see supplementary
material, Figure S1B,C).
Although the distribution of ER-positive and proges-
terone receptor (PgR)-positive indices in primary tumors
and PDXs were similar (see supplementary material,
Table S1 and Figure S2A,B), they differed by >10% in
five and 12 pairs, respectively, consistent with higher
inter- and intratumor variability of PgR staining in
clinical samples (see supplementary material, Figure
S2C,D). HER2 status was IHC 3+ in two of three PDXs
corresponding to IHC 3+ primary tumors, including one
confirmed by FISH. A primary tumor with an IHC 2+
score and focal gene amplification was negative in the
PDX, suggesting clonal outgrowth.
The PDXs showed four distinct architectural pat-
terns reminiscent of human breast disease: flat (F),
lobular (LOB), in situ (IS) and invasive (INV) in pure
form or mixed. The F pattern (Figure 2A–E) resembled
columnar cell changes and flat epithelial atypia, an
early premalignant alteration [11,12], showing a mono-
layer lining of variably dilated mouse ducts (Figure 2A)
with large columnar cells, mild nuclear pleomorphism
and abundant eosinophilic cytoplasm forming apical
‘snouts’ (Figure 2B). It was associated with foci of intra-
ductal proliferation of low nuclear grade tumor cells in a
cribriform pattern, similar to atypical ductal hyperplasia
(Figure 2E) [12]. Strong and diffuse ER (Figure 2D) and
PgR expression (Figure 2E) were observed. Together
this pattern was interpreted as early ‘colonization’ of
murine ducts by human tumor cells.
The LOB pattern was characterized by tumor cell
growth within the ductal walls, like pagetoid spread
of lobular carcinoma in situ (LCIS) (Figure 2F,G, sup-
plementary material, Figure S3) [12,13], associated
with intracellular clear, mucin-like vacuoles bestowing
a signet-ring cell-like appearance on the tumor cells
(Figure 2F). Interestingly, four of five lobular PDXs cor-
responded to this pattern; no typical LCIS was observed,
instead four of them exhibited the F pattern. In the
human breast, columnar cell changes and lobular neo-
plasia are frequently associated and considered as ‘low
grade’ precursor lesions of both ductal and lobular sub-
types [14,15]. The only case of pleomorphic lobular car-
cinoma showed LOB and F patterns with a 20% prolif-
erative fraction (Figure 1B).
The IS pattern showed varying degrees of filling of
the ductal lumen by tumor cells (Figure 2H–O) and
resembled ductal carcinoma in situ (DCIS). It encom-
passed combinations of different degrees of nuclear
pleomorphism and architectural patterns, like cribriform
(Figure 2H–J) or solid with or without comedonecro-
sis (Figure 2K–O) [12]. An ER-positive HER2-positive
PDX showed large tumor extent, high nuclear pleo-
morphism, comedo architecture, high proliferation rate
(Figure 2M) and HER2 overexpression (Figure 2O).
Although the tumor cells were derived from invasive
primary tumors, only one-third of the PDXs had an INV
pattern, with tumor cells detected outside the host ducts,
either isolated or in small clusters (Figure 2P–R). Thus,
intraductal xenografts replicate earlier stages than the
original primary tumor; nevertheless, micrometastases
were present in 90% of the mice and in all the 16
analyzed PDXs (see supplementary material, Table S1).
Next, we assessed how the biological features of the
PDXs related to the prognostic characteristics of their
clinical counterparts. According to a 20% Ki67 IHC
cut-off based on clinical practice [16], the primary tumor
series comprised seven luminal A-like (Ki67< 20%)
and 14 luminal B-like (Ki67≥ 20%) cases; four of the
latter were HER2-positive. In luminal A-like cases, the F
pattern was observed in six of seven PDXs, pure in three
cases, mixed with IS in one and with the LOB pattern in
two cases. No INV pattern was found and the IS pattern
was only found in one case (Figures 1B and 3A). Nine
of 14 luminal B-like cases, all of no special type (NST)
(12) showed the F pattern, only 2 of them as the only
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2019; 247: 287–292
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Figure 1. Intraductal ER-positive BC PDXs. (A) Experimental scheme of PDX establishment and follow-up. Primary tumors were dissociated to
single cells, which were subsequently transduced with lentivirus encoding GFP and luciferase. The infected cells were injected intraductally
in multiple glands and their in vivo growth monitored by bioluminescence. The mice were euthanized and the presence of metastases
assessed by bioluminescence in brain, lungs, bones and liver. Analysis of spleen, intestine and other internal organs was negative. (B) Table
reporting primary tumor and PDX characteristics. (C) Hemalum/eosin-stained section of a micrometastasis*** in the lung, consisting of
atypical cells with large nuclei. Inset: IHC staining for ER (brown) with Mayer’s hematoxylin counterstain of an adjacent section revealing
the ER-positive tumor cells in the ER-negative lung tissue. Scale bars = 35 μm. (D) Numbers of different organs (n = 88) in 31 xenografted
mice bearing micrometastases.
pattern (Figure 3A). The INV pattern was detected in six
of 14; IS and INV patterns were combined in four of 14.
Thus, the F pattern tended to be present in luminal A-like
BC-derived PDXs. IS and INV patterns on the contrary
were observed, with or without the associated F pattern,
in PDXs obtained from the more aggressive luminal
B-like subtype. Micrometastatic burden was higher in
mice engrafted with luminal B-like than luminal A-like
primary tumors (Figure 3B).
Tumor extent did not correlate with the time the
grafted cells spent in the hosts (Figure 3C) nor with
the number of cells injected (Figure 3D) but with in
vivo growth rates (Figure 3E) and Ki67 index in the
primary tumor (Figure 3F). The proliferative indices
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2019; 247: 287–292
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Figure 2. Intraductal PDXs exhibit four morphological patterns by hemalun/eosin staining and IHC. (A–E) Flat (F) pattern. (A–C) Human
tumor cells cover the wall of variably dilated ducts forming a monolayer of large cylindrical cells with small nuclei, eosinophilic cytoplasm
and apical cytoplasmic ‘snouts’ reminiscent of columnar cell changes and flat epithelial atypia in the human breast. (D and E) ER (D) and PgR
(E) are strongly and diffusely expressed by human cells. (E) Focally, transition between the F pattern and cellular bridges similar to human
atypical ductal hyperplasia is seen. (F and G) Lobular (LOB) pattern. (F) The mouse ductal epithelium is replaced by human cells harboring
two associated phenotypes: (1) large cells with a ‘signet ring cell’ appearance (a large cytoplasmic vacuole displaces an enlarged nucleus
toward the periphery of the cell) grow within the ductal wall in a ‘pagetoid’ manner; (2) smaller cohesive cubo-cylindrical cells lining the
ductal lumen. (G) ER is expressed in most large cells and in a few cylindrical cells. (H–O) In situ (IS) pattern. Human tumor cells fill the
ductal lumen. (H–J) Some IS PDXs exhibit a cribriform architectural pattern, mild nuclear pleomorphism, low proliferation index (Ki67) (I)
and diffuse strong ER expression (J). (K–O) One PDX exhibits a solid growth with comedonecrosis (K), marked nuclear pleomorphism (L and
N), high proliferation index (Ki67) (M) and HER2 overexpression (O). (P–R) Invasive pattern (INV). Tumor cells diffusely expressing ER fill
the dilated mouse ductal tree (P and Q) and grow outside the ducts in small clusters surrounded by collagen (P, R arrows). Scale bars =
100 μm.
in primary tumors also correlated with in vivo growth
rates (Figure 3G) and micrometastatic load (Figure 3H).
Thus, tumor extent relates to primary tumor biology
rather than to engraftment modalities; growth rates and
micrometastatic burden reflect Ki67 index and hence
patient prognosis.
Discussion
The intraductal PDXs of ER-positive BCs in this study
reproduce the spectrum of ER-positive DCIS with dif-
ferent architectures: solid, comedo and cribriform, com-
bined with various degrees of nuclear pleomorphism
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2019; 247: 287–292
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Figure 3. Characterization of in vivo growth. (A) Distribution of histological patterns within each subtype. (B) Micrometastatic burden
expressed as percentage of positive organs in each recipient in luminal A- (LumA) versus luminal B- (LumB) derived PDXs. (C–F) Pearson
correlation of tumor extent against (C) time of PDX growth in vivo, expressed in days after injection, (D) initial number of cells injected
per gland, (E) in vivo cell growth expressed as fold-change radiance relative to the first day of measurement (log10) and (F) Ki67 index of
the primary tumor. (G and H) Pearson correlation of primary tumor Ki67% with (G) in vivo monitored growth and with (H) micrometastatic
burden the percentage of organs affected by metastases within each case as determined by bioluminescence.
[12,13,17]. Several precursor lesions, such as flat epithe-
lial atypia, atypical ductal hyperplasia, pagetoid growth
of LCIS, were observed, whereas typical aspects of
LCIS were not. Invasive cancer occurred only as small
foci and no true invasive lobular carcinomas or other
special subtypes were observed in the 21 PDXs under
study.
Hence, most histopathological features are tumor
cell-intrinsic and not determined by stroma or sys-
temic factors, which differ between humans and mice.
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2019; 247: 287–292
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The observation that two-thirds of the PDXs derived
from invasive cancers represent earlier lesions sug-
gests that engrafted cells re-start growth intraductally,
recapitulating different steps with a prolonged stage
of non-invasive growth as they probably did in the
patient’s breast years before diagnosis. This is impor-
tant to consider when using the model in personalized
medicine [9].
Although the typical F, LOB and IS patterns are
readily identified, some morphological aspects of
ER-positive intraductal PDX are more difficult to clas-
sify. This concerns dispersed foci of human cells lining
the wall of small mouse ducts, with neither apical snouts
nor cystic duct dilation. We classified these as F but
speculate that they will evolve into a different pattern.
Although most (15/21) PDXs had some F pattern, it
tended to be pure in luminal A-derived PDXs, whereas
IS and INV patterns were detected when luminal B cells
were engrafted. Furthermore, proliferative indices of
primary tumors were maintained in the PDXs. Thus, the
heterogeneity of luminal tumors was preserved. This is
especially important regarding the clinical problem of
overtreatment; the model may help identify tumors with
low aggressiveness and/or a high level of responsiveness
to endocrine therapy.
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